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Module One
History of
Disease and
Vaccines

Learning Objective :
The learner will after completion of this module will:
Describe the history of Vaccines
Identify the vaccine preventable diseases.

Identify appropriate recommended vaccines and the
schedule of delivery.
Describe the difference between traditional vaccines and
MRNA
List reasons to vaccinate

Choose the correct answer.
1.
a.
b.
c.

The oral history of use of vaccine was smallpox in
1000 AD in India
750 AD in Africa
600 AD in Europe

2.
a.
b.
c.
d.

Choose the diseases cannot be prevented by vaccine
Measles
Pertussis
Diabetes
HPV

3.
a.
b.
c.
d.

The vaccine schedule for children begins at:
Birth
Two months
Four months
Nine months

4. MRNA vaccines are different because
a. The vaccine uses a weakened virus that activates are immune system
b. The vaccine uses a live virus that activates are immune system
c.
The vaccine teaches the body to make a protein that activates the immune response.
d. The vaccine is an antibody which produces an immune response.

This is a brief overview of the history of vaccines.
Please view this You Tube Video 1

•

Nova : History of Vaccines

•

https://www.bing.com/videos/search?view=detail&mid=7807F5B7
AAF52B232EB17807F5B7AAF52B232EB1&q=history of vaccination
nova&shtp=GetUrl&shid=5295caaf-daba-4100-8ac764b03d694b10&shtk=Tk9WQTpBIEhpc3Rvcnkgb2YgVmFjY2luYXRp
b24gU2Vhc29uIDQxIEVwaXNvZGUgMTQ%3D&shdk=VmFjY2luYXRp
b24gYmVnYW4gYXMgYSB0cmFkaXRpb25hbCB0aGVyYXB5IG92ZXIg
YSB0aG91c2FuZCB5ZWFycyBhZ28u&shhk=OaT5qjEwWBoYKbUoJZ
q4BJFAdK%2BiwkhwFclMQC5YiT8%3D&form=VDSHOT&shth=OVP.
ciR5Lqao_AXhRzRbokaJFgEsCd

• Use of vaccine is a form of health promotion
and prevention of illness and has improved life
expectancy in the US today
• Every birth cohort vaccinated with the routine
immunization schedule (this includes DTap, Td,
Hib, Polio, MMR, Hep B, and varicella vaccines),
society:
• Saves 33,000 lives.
• Prevents 14 million cases of disease.
• Reduces direct health care costs by $9.9
billion.
• Saves $33.4 billion in indirect costs

• Immunization and Infectious Diseases |
Healthy People 2020

Easy-to-read Immunization Schedule by Vaccine for Ages Birth-6 Years | CDC
Vaccine Preventable diseases
Disease
Chickenpox

Vaccine
Varicella vaccine protects against
chickenpox.

Disease spread by
Air, direct contact

Disease symptoms
Rash, tiredness, headache, fever

Disease complications
Infected blisters, bleeding disorders,
encephalitis (brain swelling), pneumonia
(infection in the lungs)

Diphtheria

DTaP* vaccine protects against diphtheria. Air, direct contact

Sore throat, mild fever, weakness, swollen Swelling of the heart muscle, heart failure,
glands in neck
coma, paralysis, death

Hib

Hib vaccine protects against Haemophilus Air, direct contact
influenzae type b.

Hepatitis A

HepA vaccine protects against hepatitis A. Direct contact, contaminated food or
water

May be no symptoms unless bacteria enter Meningitis (infection of the covering
the blood
around the brain and spinal cord),
intellectual disability, epiglottitis (lifethreatening infection that can block the
windpipe and lead to serious breathing
problems), pneumonia (infection in the
lungs), death
May be no symptoms, fever, stomach pain, Liver failure, arthralgia (joint pain), kidney,
loss of appetite, fatigue, vomiting, jaundice pancreatic, and blood disorders
(yellowing of skin and eyes), dark urine

Hepatitis B

HepB vaccine protects against hepatitis B. Contact with blood or body fluids

May be no symptoms, fever, headache,
Chronic liver infection, liver failure, liver
weakness, vomiting, jaundice (yellowing of cancer
skin and eyes), joint pain

Influenza (Flu)

Flu vaccine protects against influenza.

Air, direct contact

Fever, muscle pain, sore throat, cough,
extreme fatigue

Pneumonia (infection in the lungs)

Tetanus

DTaP* vaccine protects against
tetanus.

Exposure through cuts in skin

Stiffness in neck and abdominal
muscles, difficulty swallowing,
muscle spasms, fever

Broken bones, breathing difficulty,
death

Easy-to-read Immunization Schedule by Vaccine for Ages Birth-6 Years | CDC

Measles

MMR** vaccine protects against measles.

Air, direct contact

Rash, fever, cough, runny nose, pink eye

Encephalitis (brain swelling), pneumonia
(infection in the lungs), death

Mumps

MMR**vaccine protects against mumps.

Air, direct contact

Swollen salivary glands (under the jaw),
fever, headache, tiredness, muscle pain

Meningitis (infection of the covering around
the brain and spinal cord), encephalitis (brain
swelling), inflammation of testicles or ovaries,
deafness

Pertussis

DTaP* vaccine protects against pertussis
(whooping cough).

Air, direct contact

Severe cough, runny nose, apnea (a pause in
breathing in infants)

Pneumonia (infection in the lungs), death

Polio

IPV vaccine protects against polio.

Air, direct contact, through the mouth

May be no symptoms, sore throat, fever,
nausea, headache

Paralysis, death

Pneumococcal

PCV13 vaccine protects against
pneumococcus.

Air, direct contact

May be no symptoms, pneumonia (infection
in the lungs)

Bacteremia (blood infection), meningitis
(infection of the covering around the brain and
spinal cord), death

Rotavirus

RV vaccine protects against rotavirus.

Through the mouth

Diarrhea, fever, vomiting

Severe diarrhea, dehydration

Rubella

MMR** vaccine protects against rubella.

Air, direct contact

Sometimes rash, fever, swollen lymph nodes

Very serious in pregnant women—can lead to
miscarriage, stillbirth, premature delivery,
birth defects

Diphtheria
Review the previous chart.
• How does diphtheria spread?

• What are the symptoms of
diphtheria?
• What are the possible
complications of the disease?

Diphtheria
• How is diphtheria spread?

Air and Direct contact
• What are the symptoms of diphtheria?
Sore throat, mild fever, weakness, swollen
glands in neck
• What are the possible complications of
the disease?
Swelling of the heart muscle, heart failure,
coma, paralysis, death

• https://www.youtube.com/
watch?v=yhP6-07O4Hw

• Importance of a Vaccine
Schedule

Importance of a Vaccines for
Children Dr. Paul Offit from The
Children’s Hospital of Philadelphia

• https://www.youtube.com/
watch?v=t401wOp6C8U

Birth 5-15 months and 18 months to 18 years second slide
Vaccine
Hepatitis B (HepB)

Birth
st
1 dose

1 mo

2 mos

4 mos

9 mos

6 mos

nd

st

1 dose

Diphtheria, tetanus, &
acellular pertussis
(DTaP: <7 yrs)

1 dose

Haemophilus
influenzae type b
(Hib)
Pneumococcal
conjugate
(PCV13)
Inactivated poliovirus
(IPV: <18 yrs)

1 dose

st

st

st

1 dose
st

1 dose

nd

2 dose

nd

2 dose

nd

2 dose
nd

2 dose

See notes

th

rd

3 dose

←4 dose→
rd

See notes

Human papillomavirus
(HPV)
Meningococcal
(MenACWY-D ≥9 mos,
MenACWY-CRM ≥2 mos,
MenACWY-TT ≥2years)
Meningococcal
B (MenB)
Pneumococcal
polysaccharide
(PPSV23)
Birth-18 Years Immunization Schedule | CDC

th

←3 or 4 dose,
See notes→
th

rd

3 dose

←4 dose→

nd

rd

2 dose

←3 dose→

Influenza (IIV)

Hepatitis A
(HepA)
Tetanus, diphtheria, &
acellular pertussis
(Tdap: ≥7 yrs)

15 mos

←3 dose→

Rotavirus
(RV) RV1 (2-dose series);
RV5 (3-dose series)

Influenza (LAIV4)
Measles, mumps,
rubella
(MMR)
Varicella
(VAR)

12 mos
rd

←2 dose→

Annual vaccination 1 or 2 doses

See notes

st

←1 dose→
st

←1 dose→
See notes

See notes

←2-dose series, See notes→

Vaccines
Hepatitis B
(HepB)

18 mos
rd
←3 dose→

19-23 mos

2-3 yrs

4-6 yrs

7-10 yrs

11-12 yrs

13-15 yrs

16 yrs

Rotavirus
(RV) RV1 (2-dose
series); RV5 (3-dose
series)
Diphtheria, tetanus,
& acellular
pertussis
(DTaP: <7 yrs)

th

th

←4 dose→

5 dose

Haemophilus
influenzae type b
(Hib)
Pneumococcal
conjugate
(PCV13)
Inactivated poliovirus
(IPV: <18 yrs)

rd

th

←3 dose→

Influenza (IIV)

4 dose
Annual vaccination 1 or 2 doses

Annual vaccination 1 dose only
Annual vaccination 1 dose only

Influenza (LAIV4)

Annual vaccination 1 or 2 doses

Measles, mumps,
rubella
(MMR)

2 dose

Varicella
(VAR)

2 dose

Hepatitis A
(HepA)

nd

nd

← 2-dose series, See notes→

Tetanus, diphtheria, &
acellular pertussis
(Tdap: ≥7 yrs)

Tdap

Human
papillomavirus
(HPV)
Meningococcal
(MenACWY-D ≥9 mos,
MenACWY-CRM ≥2
mos, MenACWY-TT
≥2years)

See notes
*
See notes

st

1 dose

Meningococcal B
(MenB)
Pneumococcal
polysaccharide
(PPSV23)
Birth-18 Years Immunization Schedule | CDC

nd

2 dose

See notes
See notes

17-18 yrs

Review the previous immunization
charts

• When is the first dose of Varicella given?
• When is the first dose of Hep B given?

• When is the second dose of measles, mumps and
rubella given?

ACIP Adult
Immunization
Schedule

https://youtu.be/3TyRY0LGYpQ

Adult Immunization Schedule for ages 19 and older, 2021
Vaccine
Influenza inactivated (IIV)
or
Influenza
recombinant (RIV4)

19-26 years

27-49 years
1 dose annually

50-64 years

1 dose annually
Influenza live attenuated
(LAIV4)
Tetanus, diphtheria,
1 dose Tdap each pregnancy; 1 dose Td/Tdap for wound management (see notes)
pertussis
1 dose Tdap, then Td or Tdap booster every 10 years
(Tdap or Td)
Measles, mumps, rubella
1 or 2 doses depending on indication (if born in 1957 or later)
(MMR)
Varicella
2 doses (if born in 1980 or later)
(VAR)
Zoster recombinant
(RZV)
27 through 45 years
Human papillomavirus
2 or 3 doses depending on age
(HPV)
at initial vaccination or
condition
Pneumococcal conjugate
1 dose
(PCV13)
Pneumococcal
1 or 2 doses depending on indication
polysaccharide
(PPSV23)
Hepatitis A
2 or 3 doses depending on vaccine
(HepA)
Hepatitis B
2 or 3 doses depending on vaccine
(HepB)
Meningococcal A, C, W, Y
1 or 2 doses depending on indication, see notes for booster recommendations
(MenACWY)
2 or 3 doses depending on vaccine and indication, see notes for booster recommendations
Meningococcal B
(MenB)
19 through 23 years
Haemophilus
1 or 3 doses depending on indication
influenzae type b
(Hib)

≥65 years

2 doses

2 doses

1 dose

1 dose

Review the previous chart.
• What adults require the
varicella vaccine?
• At what age should the adult
take the pneumococcal
vaccine?
• At what age should the adult
take the zoster vaccine?

• What adults require the
varicella vaccine?
2 doses if born before 1980
• At what age should the adult
take the pneumococcal
vaccine?

65 and above
• At what age should the adult
take the zoster vaccine?
50 and above

Nova: The MRNA vaccine You Tube Video (2)

• https://www.bing.com/videos/search?view=detail&mid=CB3BAA7AC0C9BF00847CCB3BAA7AC0C9BF008
47C&q=history of vaccination nova&shtp=GetUrl&shid=3f22ccc2-a7a6-431a-a5d8947cad2ae172&shtk=Q2FuIFNjaWVudGlzdHMgVXNlIFJOQSB0byBDcmVhdGUgYSBDb3JvbmF2aXJ1cyBWY
WNjaW5lPyBJIE5PVkEgSSBQQlM%3D&shdk=U2NpZW50aXN0cyBhcmUgdHJ5aW5nIG5ldywgcmV2b2x1dG
lvbmFyeSB0ZWNobmlxdWVzIHRvIG1ha2UgYSBTQVJTLUNvVi0yIHZhY2NpbmUsIGJ1dCBmYWNlIGNoYWxsZ
W5nZXMgYWxvbmcgdGhlIHdheS4gUFJPRFVDVElPTiBDUkVESVRTOiBQcm9kdWNlZCBhbmQgTmFycmF0Z
WQgYnk6IEFyaSBEYW5pZWwgUmVzZWFyY2ggYW5kIFByb2R1Y3Rpb246IENhaXRsaW4gU2FrcyBhbmQgT
WFkZWxpbmUgV2VpciBCKSAyMDIwIFdHQkggRWR1Y2F0aW9uYWwgRm91bmRhdGlvbiBNRURJQSBDUkV
ESVRTOiBBZGRpdGlvbmFsIEZvb3RhZ2UgYW5kIFZpc3VhbHM6IEVkZ2V3b3J4IFN0dWRpb3MgU2NpZW50a
WZpYyAuLi4%3D&shhk=4u8ZLsP2qSzFJp5YoCBy2WYzt1Oe6BEl1I4aZH4fDAI%3D&form=VDSHOT&shth=OV
P.BKAMQC2iH1UeUbiWEiLmdwHgFo

Post Test
1.

The oral history of use of vaccine was smallpox in

a.

1000 AD in India

b.

750 AD in Africa

c.

600 AD in Europe

2.

Choose the diseases cannot be prevented by vaccine

a.

Measles

b.

Pertussis

c.

Diabetes

d.

HPV

3.

The vaccine schedule for children begins at:

a.

Birth

b.

Two months

c.

Four months

d.

Nine months

4. MRNA vaccines are different because
a.

The vaccine uses a weakened virus that activates are immune system

b.

The vaccine uses a live virus that activates are immune system

c.

The vaccine teaches the body to make a protein that activates the immune response.

d.

The vaccine is an antibody which produces an immune response.

1.

A. 1000 AD India

2.

B. Diabetes

3.

A. Birth

4.

C. The vaccine teaches the body to make a protein
that activates the immune response

Please Proceed to
Module 2

Health Promotion within HighRisk Communities: Become an
agent of Change to Enhance
Vaccination Acceptance in
Communities

Module 2
Public Health and
Infectious Disease

Chain of
infection
Cycle

Chain of
infection –
VIDEO

• https://www.bing.com/videos/search?view=detail&mid=0
CE35DEB71215DC012EA0CE35DEB71215DC012EA&q=Chai
n of Infection Nursing&shtp=GetUrl&shid=0763d3bb-64fc48e8-9b9f66f8248b00af&shtk=QUhFOiBUaGUgQ2hhaW4gb2YgSW5
mZWN0aW9u&shdk=VXNpbmcgdGhlIHRyYWluLXRoZS10c
mFpbmVyIG1vZGVsLCB0aGUgQ2VydGlmaWVkIEhlYWx0aC
BDYXJlIEVudmlyb25tZW50YWwgU2VydmljZXMgVGVjaG5p
Y2lhbiAoQ0hFU1QpIGRlc2lnbmF0aW9uIHNldHMgbmF0aW
9uYWwgc3RhbmRhcmRzIHNwZWNpZmljYWxseSBmb3IgZ
W52aXJvbm1lbnRhbCBzZXJ2aWNlcyB0ZWNobmljaWFucyB
3b3JraW5nIGluIGhlYWx0aCBjYXJlLg%3D%3D&shhk=HjxePq
NdxNB0Er%2BT4F9F6P1Cn6ajj4Pbml6F8Dgz5Hk%3D&form
=VDSHOT&shth=OVP.K_IkReevgOyyqbokoqdMOwHgFo

Diseases and Portals of infection
What is a portal of infection?

What is the portal of entry for
chickenpox?

What is the portal of entry for
influenza?

Disease and Portals of Infection
What is a portal of infection?
Microorganism enters a susceptible host
What is the portal of entry for chickenpox?
Droplet. Face to face contact.

What is the portal of entry for influenza?
Direct contact with infected individuals, touching contaminated objects and by inhalation.

emedia.rmit.edu.au/infection_control/content/4_PortalEnt

Basic Standard Precautions
https://youtu.be/IisgnbMfKvI
Johns Hopkins
• Personal Protective Equipment
(PPE) 101 (cdc.gov)

• After reviewing the videos please
answer the following question on
the next slide.

• Scenario 1
Why are only gloves needed?

• Scenario 2
What is the rationale for
gloves, gown, mask/googles or
face shield?

• Scenario 1

Why are only gloves needed?
Refer to Speaker notes Slide 7

• Scenario 2
What is the rationale for gloves,
gown, mask/googles or face shield?
Refer to Speaker Notes Slides 7,10
and 13.

Donning Personal Protective Equipment
• https://youtu.be/H4jQUBAlBrI

Watch this video CDC video on
Donning protective equipment
and answer the questions on
the next slide.

Donning PPE
• The first step prior to donning PPE.

• What is the first step when donning an N95 mask.

• What is the last step of donning .

Donning PPE
• The first step prior to donning PPE.
• Wash your hands
• What is the first step when donning an N95 mask.
Cup mask in your hands and place over your nose and mouth extend
under chin.

• What is the last step of donning .
• Don your gloves.

Infectious Diseases
• https://youtu.be/2JWku3Kjpq0
Think about these questions as you watch
the video.

• What is the epidemiological Triad
• What role does vaccine play
• What is herd immunity

Infectious diseases

• What is the epidemiological Triad
Agent, Host, Environment
• What role does vaccine play
Vaccination can reduce or eradicate an infectious disease
• What is herd immunity
A large portion of the population has immunity through vaccination or
disease.

Infectious disease
• https://youtu.be/9axOFtPqS0c
• Name two causes of infectious disease.
• What is the infectious period.
• What is the secondary case rate.

Infectious diseases
• Name two causes of infectious disease.
Virus, bacteria, fungi, parasite
• What is the infectious period.
The period when the person has no symptoms but can spread the
infection
• What is the secondary case rate.
The number of people than can be infected by one infected person

Vulnerable Populations and precision vaccines
Please watch the video

• https://www.ted.com/talks/ofer_levy_the_new_science_of_personalized_vaccin
es?utm_campaign=tedspread&utm_medium=referral&utm_source=tedcomshare

• Who are considered vulnerable populations?

• What role does vaccines have for vulnerable people?

• Who are considered vulnerable populations in this video?
Children and the elderly

• What role does vaccines have for vulnerable people.
Vaccine has almost eradicated Hemophilus bacterial infection

Public Health and Social Determinants
• As you watch this video think about Social determinates and vulnerable population for
vaccine policy.
• https://www.bing.com/videos/search?view=detail&mid=983DD9AA2EE0AA6CCDF3983D
D9AA2EE0AA6CCDF3&q=YOU TUBE cdc social
determinants&shtp=GetUrl&shid=1c2964c3-669b-4e30-a4ec4f90d5fbc45e&shtk=QmV5b25kIHRoZSBEYXRhIOKAkyBQdWJsaWMgSGVhbHRoIExhdzog
U29jaWFsIERldGVybWluYW50cyBvZiBIZWFsdGggYW5kIFB1YmxpYyBIZWFsdGggMy4wLg
%3D%3D&shdk=RHIuIEpvaG4gSXNrYW5kZXIgYW5kIERyLiBLYXJlbiBEZVNhbHZvLCBBY3Rp
bmcgQXNzaXN0YW50IFNlY3JldGFyeSBmb3IgSGVhbHRoLCBkaXNjdXNzIHRoZSByb2xlIG9
mIHB1YmxpYyBoZWFsdGggaW4gdGhlIHJlY292ZXJ5IG9mIE5ldyBPcmxlYW5zIGFmdGVyIEt
hdHJpbmEsIHNvY2lhbCBkZXRlcm1pbmFudHMgb2YgaGVhbHRoLCBhbmQgd2hhdCBpcyB
uZWVkZWQgdG8gZ2V0IHRvIHB1YmxpYyBoZWFsdGggMy4wLiBDb21tZW50cyBvbiB0aGlzI
HZpZGVvIGFyZSBhbGxvd2VkIGluIGFjY29yZGFuY2Ugd2l0aCBvdXIgY29tbWVudCBwb2xpY3
k6IGh0dHA6Ly93d3cuY2RjLmdvdi9Tb2NpYWxNZWRpYSAuLi4%3D&shhk=KLgxsiN0WsdD
u9Jc4YAQkqW1BN7SteBjHHIlK89PufU%3D&form=VDSHOT&shth=OVP.TrjLvWNCYinFsdVa
NFpzYAEsDh
• Review Social Determinants | Healthy People 2020

Congratulation! Please move on to Module 3
SAR COV-2

Health Promotion within High-Risk
Communities: Become Agents of
Change to Enhance Vaccination
Acceptance in Their Communities
Module 3

Module 3- SAR-COV 2
After completing this module the student will :

Identify the symptoms related to COVID-19 .
Describe the different vaccines available for prevention of COVID-19 infection.
Describe the process that makes these vaccines safe.
Discuss population health and social determinants related to COV-2.

COVID -19
• Coronavirus Disease 2019
(COVID-19) | Disease or
Condition of the Week | CDC

COVID -19

Coronavirus Disease 2019 (COVID-19) | Disease or
Condition of the Week | CDC

SARS COV-2
Symptoms
Coronavirus Disease 2019 (COVID-19) | Disease or
Condition of the Week | CDC

Emergency
Medical
Care
Coronavirus Disease 2019 (COVID-19) |
Disease or Condition of the Week | CDC

Name three mild symptoms that a person could have if you have COVID-19.
Fever or chills, Cough, Shortness of breath or difficulty breathing, fatigue, muscle or body aches,
headache, new loss of taste or smell, sore throat, congestion or runny nose, nausea or vomiting, diarrhea

Name three severe symptoms that a person could have if they have COVID-19.
Trouble breathing, persistent pain or pressure in the chest, new confusion, inability to wake or stay
awake, pale, gray, or blue-colored skin, lips, or nail beds, depending on skin tone
Does everyone have who has COVID-19 have severe symptoms?
No but elderly people and individuals with underlying disease are at greater risk.

Difference
between
COVID-19
& Flu

testing

National
Center for Immunization and Respiratory Diseases
(NCIRD) Division of Viral Diseases

mRNA vaccines

Types of
Vaccines

Vector vaccines

Understanding How COVID-19 Vaccines Work | CDC

Pfizer-BioNTech

Vaccines for
COVID-19

Moderna

Johnson & Johnson’s Janssen

• How do mRNA vaccines work?

• How do vector vaccines work?

• Name one mRNA and one vector vaccine?

Adverse Events

• Cases of myocarditis and pericarditis in adolescents
and young adults have been reported more often after
getting the second dose than after the first dose of one
of the two mRNA COVID-19 vaccines, Pfizer-BioNTech
or Moderna.

•
Last Updated Sept. 1, 2021Content source: National Center for
Immunization and Respiratory Diseases (NCIRD), Division of
Viral Diseases

How do you know the
Vaccines are safe?

FDA and Clinical Trials
•

Phase 1 trials are small, involving only 20 to 100 volunteers, and last only a few months. The purpose of phase one trials
is to evaluate basic safety and identify very common reactions.

•

Phase 2 trials are larger and involve several hundred participants. These studies last anywhere from several months to
two years and collect additional information on safety and efficacy. Data gained from phase two trials can be used to
determine the composition of the vaccine, how many doses are necessary, and a profile of common reactions.

•

Phase 3 trials are the next step, unless the vaccine is ineffective or causes health problems, and are expanded to involve
several hundred to several thousand volunteers. Typically, these trials last several years. Because the vaccinated group
can be compared to those who have not received the vaccine, researchers are able to identify true reactions.

US Vaccine Safety : Overview History
https://www.cdc.gov/vaccinesafety/ensuringsafety/history/index.html

Vaccine Life
Cycle
• US Vaccine Safety :
Overview History
• https://www.cdc.gov/
vaccinesafety/ensurings
afety/history/index.htm
l

Biologics
License
Application

•

If the clinical trials demonstrate that the vaccine is safe and effective, the manufacturer
submits a Biologics License Application (BLA) to FDA .

•

The FDA reviews the clinical trial data and proposed product labeling.

•

The FDA inspects the plant and goes over manufacturing protocols to ensure vaccines are
produced in a safe and consistent manner.

•

Only after the FDA is satisfied that the vaccine is safe is it licensed for use in the general
population.

US Vaccine Safety : Overview History
https://www.cdc.gov/vaccinesafety/ensuringsafety/history/index.html

• Describe clinical
trials?

•

Describe clinical trials?

•

Phase 1 trials are small, involving only 20 to 100
volunteers, and last only a few months. The purpose of
phase one trials is to evaluate basic safety and identify
very common reactions.

•

Phase 2 trials are larger and involve several hundred
participants. These studies last anywhere from several
months to two years and collect additional information
on safety and efficacy. Data gained from phase two
trials can be used to determine the composition of the
vaccine, how many doses are necessary, and a profile
of common reactions.

•

Phase 3 trials are the next step, unless the vaccine is
ineffective or causes health problems, and are
expanded to involve several hundred to several
thousand volunteers. Typically, these trials last several
years. Because the vaccinated group can be compared
to those who have not received the vaccine,
researchers are able to identify true reactions.

Population and Social Determinants of Health
Please review:
King County Monitors the Ongoing Economic, Social, and Health Effects of COVID-19
(cdc.gov)

Please watch:
Motivate to Vaccinate: National Month of Action for COVID-19 Vaccines - YouTube

• What would you do to motivate
vaccination?

Congratulations!
Please move on to Module 4

MODULES 4-6
Safe And Effective Adult
Vaccine Administration For
Health Care Professionals

LEARNING OUTCOMES

At the completion of this module the learner will

✓1. Complete a formal assessment of readiness to safely administer vaccines.
✓2. Perform a self evaluation of areas for enhancement or radiation prior to
administering a vaccination

✓3. Identify the resources available to health professionals for training
✓4. Identify hazards to health care workers administering vaccinations and discuss
safety practices designed to mitigate risk.

✓5. Complete a CDC approved training course: You Call the Shots
✓6. Upload a certification of completion for this course.

MODULE FOUR
SAFE AND EFFECTIVE
VACCINE ADMINISTRATION
FOR ADULTS

PART I
PROFESSIONAL
EDUCATION

PREPARATION
Safe Vaccine Administration begins well in advance of the patient encounter

• CDC recommends that all health care personnel

who administer vaccines receive comprehensive,
competency-based training on vaccine
administration policies and procedures BEFORE
administering vaccines.

EDUCATE THE
VACCINATOR

• Comprehensive, skills-based training should be

integrated into existing staff education programs
such as new staff orientation and annual
education requirements.

• A free vaccine administration e-Learn is available
that offers continuing education for health care
personnel, including CME, CNE, CEU, CPE, CPH,
and CHES.

• Proper vaccine administration is a 2 step process:

SAFE VACCINE
ADMINISTRATION
HTTPS://WWW.CDC.GOV/VACCINES/HCP/INDEX.HTML

Step One is EDUCATION which is critical to ensure
that vaccination is safe and effective. CDC
recommends that all health care personnel who
administer vaccines receive comprehensive,
competency-based training on vaccine
administration policies and procedures BEFORE
administering vaccines.

• Step two is Comprehensive skills-based training

should be integrated into existing staff education
programs such as new staff orientation and
annual education requirements. A free vaccine
administration e-Learn is available that offers
continuing education for health care personnel,
including CME, CNE, CEU, CPE, CPH, and CHES.

SAFE VACCINE
ADMINISTRATION

•

The CDC and ACIP offer specific training and
guidance for all Health Care Professionals .

•

Visit https://www.cdc.gov/vaccines/ed/index.html

•

Complete

HTTPS://WWW.CDC.GOV/VACCINES/HCP/INDEX.HTML

https://www.cdc.gov/vaccines/ed/courses.html#shots

GATHER THE FACTS

•

Review Immunization History

•

Review every patient’s immunization
history at every health care visit to assess
for needed vaccines. This includes both
routine checkups and acute-care visits.

•

Immunization histories can be found in
medical records, personal vaccination
cards, and immunization information
systems (IISs) or registries.

RESOURCES FOR HEALTH CARE
PROFESSIONALS

US vaccines by category
https://www.cdc.gov/vaccines/pubs/pinkbook/downloads/appendices/b/us-vaccines.pdf

RESOURCES FOR HEALTH CARE
PROFESSIONALS
ACTION
Verify that the vaccinator has accurate and
up to date information
https://www.cdc.gov/vaccines/hcp/vis/whatis-new.html

ASSESS FOR RISK TO HCP FROM IMMUNIZATION ADMINISTRATION

• Providers are sometimes concerned when they have the same
contraindications or precautions as their patients from whom they
withhold or defer vaccine.

• For administration of routinely recommended vaccines, there is no
evidence of risk of exposure of vaccine components to the health
care provider; therefore, conditions in the product literature labeled
as contraindications and precautions to vaccine components are not
a reason to withdraw from this function of administering the vaccine.

https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/administration.html

• https://www.cdc.gov/vaccines/hcp/acip-recs/generalrecs/administration.html

SCREEN FOR
CONTRAINDICATIONS
PRECAUTIONS

Contraindications

Precautions

• Contraindications (conditions in a

• A precaution is a condition in a recipient

recipient that increases the risk for a
serious adverse reaction) to
vaccination are conditions under
which vaccines should not be
administered.

• The majority of contraindications are
temporary, vaccinations often can be
administered later when the condition
leading to a contraindication no longer
exists

• Severely immunocompromised
persons generally should not receive
live vaccines

• Women known to be pregnant generally
should not receive live, attenuated virus
vaccines

• Persons who experienced encephalopathy
within 7 days after administration of a previous
dose of pertussis-containing vaccine not
attributable to another identifiable cause

that might increase the risk for a serious
adverse reaction, might cause
diagnostic confusion, or might
compromise the ability of the vaccine to
produce immunity

• A person might experience a more
severe reaction to the vaccine than
would have otherwise been expected

• a vaccination might be indicated in the
presence of a precaution if the benefit
of protection from the vaccine
outweighs the risk for an adverse
reaction.

• The presence of a moderate or severe
acute illness with or without a fever is a
precaution to administration of all
vaccines and should be a reason to
defer vaccination.

SCREEN FOR CONTRAINDICATIONS
Contraindications

•

Contraindications (conditions in a recipient that increases the risk for a serious adverse reaction) to vaccination
are conditions under which vaccines should not be administered.

•

The majority of contraindications are temporary, vaccinations often can be administered later when the condition
leading to a contraindication no longer exists

•

Severely immunocompromised persons generally should not receive live vaccines

•

Women known to be pregnant generally should not receive live, attenuated virus vaccines

•

Persons who experienced encephalopathy within 7 days after administration of a previous dose of pertussiscontaining vaccine not attributable to another identifiable cause should not receive additional doses of a vaccine
that contains pertussis

SCREEN FOR PRECAUTIONS
Precautions

•

A precaution is a condition in a recipient that might increase the risk for a serious adverse reaction, might cause
diagnostic confusion, or might compromise the ability of the vaccine to produce immunity

•

A person might experience a more severe reaction to the vaccine than would have otherwise been expected

•

a vaccination might be indicated in the presence of a precaution if the benefit of protection from the vaccine
outweighs the risk for an adverse reaction.

•

The presence of a moderate or severe acute illness with or without a fever is a precaution to administration of all
vaccines and should be a reason to defer vaccination.

WHAT IS AN EXAMPLE OF A CONTRAINDICATION

Look at the literature for
each vaccine.
Identify a contraindication
for each vaccine you plan
to administer.

WHAT IS AN EXAMPLE OF A PRECAUTION?

Look at the literature for
each vaccine.
Identify a precaution for
each vaccine you plan to
administer.

LEARNING ACTIVITY
•
•
•
•
•

Tdap
Hepatitis A
Hepatitis B

• MMR
• Live attenuated adult vaccines LAV’s
• Live attenuated Influenza Vaccine (LAIV)
• Varicella

HPV

Influenza

• MMR
• MMRV
• PCV13
• Polio
• Td

• Persons with most forms of altered immunocompetence

should not receive live vaccines (MMR, varicella, MMRV,
LAIV, yellow fever, Ty21a oral typhoid, BCG, smallpox, and
rotavirus).Zoster/Shingles

WHAT VACCINE IS MISSING FROM THE VIS?

MODULE FOUR
SAFE AND EFFECTIVE
VACCINE ADMINISTRATION
FOR ADULTS

PARTII
PATIENT EDUCATION

HOW WILL YOU PLAN TO
EDUCATE THE PERSON
RECEIVING THE VACCINE

Screen For
Contraindications
and
Precautions

ASSESS FOR
ALTERED IMMUNOCOMPETENCE
https://www.cdc.gov/vaccines/hcp/acip-recs/generalrecs/immunocompetence.html

EVALUATE RISK VERSUS BENEFIT

• Assess for Needed Immunizations

• HCP and patients may be at risk
• see the current Advisory Committee on Immunization
Practices (ACIP) immunization schedule to determine
what recommended vaccines are needed based on
the patient’s immunization history.

• Assess for routinely recommended vaccines at every

visit, as well as any vaccines that are indicated based
on health status, occupation, or other risk factors.

• https://www.cdc.gov/vaccines/hcp/vis/curr
ent-vis.html

GATHER THE FACTS

•

Review Immunization History

•

Review every patient’s immunization
history at every health care visit to assess
for needed vaccines. This includes both
routine checkups and acute-care visits.

•

Immunization histories can be found in
medical records, personal vaccination
cards, and immunization information
systems (IISs) or registries.

VACCINE INFORMATION STATEMENTS
ARE FOR VACCINE RECIPIENTS
• Vaccine Information Statements (VISs) are information sheets produced by the CDC that
explain both the benefits and risks of a vaccine to the recipient.

• Federal law requires that healthcare staff provide a VIS to a patient, parent, or legal
representative before each dose of certain vaccines.

• Some states have informed consent laws, covering either procedural requirements (e.g.,

whether consent may be oral or must be written) or substantive requirements (e.g., types of
information required). Check your state medical consent law to determine if there are any
specific informed consent requirements relating to immunization. VISs may be used for
informed consent as long as they conform to the appropriate state laws.
https://www.cdc.gov/vaccines/hcp/vis/index.html

COVID 19
VACCINE

•

There is not a COVID-19
Vaccine Information
Statement. COVID-19
vaccine is currently
available through
Emergency Use
Authorization (EUA) by the
Food and Drug
Administration (FDA). EUA
Fact Sheets for Recipients
should be provided to
patients at the time of
vaccination.

•

https://www.modernatx.com
/covid19vaccine-eua/

SAMPLE MODERNA INFORMATION FOR HEALTH CARE
PROFESSIONALS

•

REPORTING
ADVERSE
EVENTS

Cases of myocarditis and pericarditis in adolescents and
young adults have been reported more often after getting
the second dose than after the first dose of one of the two
mRNA COVID-19 vaccines, Pfizer-BioNTech or Moderna.

•
Last Updated Sept. 1, 2021Content source: National Center for
Immunization and Respiratory Diseases (NCIRD), Division of Viral
Diseases

MODULE FIVE
SAFE AND EFFECTIVE
VACCINE
ADMINISTRATION FOR
ADULTS
PREPARE AND DELIVER THE
VACCINE

• CDC recommends using ABHR with 6095% alcohol in healthcare settings.

• Unless hands are visibly soiled, an

GET READY

alcohol-based hand rub is preferred over
soap and water in most clinical situations
due to evidence of better compliance
compared to soap and water.

EVALUATE
Safe use of needles and syringes
• Bloodborne diseases (e.g., hepatitis B, hepatitis C, human immunodeficiency virus [HIV]) are
occupational hazards for clinicians and other health-care providers.
https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/administration.html

EVALUATE
Safe Use Of Needles And Syringes
• The Needlestick Safety and Prevention Act directed OSHA to strengthen its existing
bloodborne pathogen standards.

• To prevent inadvertent needlestick injury or reuse, safety mechanisms should be deployed
after use and needles and syringes should be discarded immediately in labeled, punctureproof containers located in the same room where the vaccine is administered (5). Used
needles should never be recapped.
https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/administration.html

Intramuscular injections
•
•

Injectable immunobiologics should be administered where local, neural, vascular, or tissue injury is unlikely.

•

Appropriate needle length depends on age and body mass. Injection technique is the most important parameter to ensure efficient intramuscular
vaccine delivery.

•

For all intramuscular injections, the needle should be long enough to reach the muscle mass and prevent vaccine from seeping into subcutaneous
tissue, but not so long as to involve underlying nerves, blood vessels, or bone.

•

. Vaccinators should be familiar with the anatomy of the area into which they are injecting vaccine. Intramuscular injections are administered at a 90degree angle to the skin, preferably into the anterolateral aspect of the thigh or the deltoid muscle of the upper arm, depending on the age of the
patient .

•

The needle gauge for intramuscular injection is 22-25 gauge. A decision on needle length and site of injection must be made for each person on the
basis of the size of the muscle, the thickness of adipose tissue at the injection site, the volume of the material to be administered, injection
technique, and the depth below the muscle surface into which the material is to be injected (. Some experts allow intramuscular injection with a ⅝inch needle but ONLY if the skin is stretched flat . If the subcutaneous and muscle tissue are bunched to minimize the chance of striking bone , a 1inch needle or larger is required to ensure intramuscular administration.

•

Aspiration before injection of vaccines or toxoids is not necessary because no large blood vessels are present at the recommended injection sites.

Use of longer needles has been associated with less redness or swelling than occurs with shorter needles because of injection into deeper muscle
mass .

SAFE USE OF NEEDLES AND SYRINGES
INTRAMUSCULAR INJECTION

SUBCUTANEOUS INJECTION

• For adults, the deltoid muscle is recommended for routine

intramuscular vaccinations . The anterolateral thigh also can be
used.

• For adults a measurement of body mass/weight is allowable prior to

vaccination, understanding that resources to measure body
mass/weight are not available in all clinical settings. For men and
women who weigh <130 lbs (<60 kg), a ⅝-inch needle is sufficient to
ensure intramuscular injection in the deltoid muscle if the injection is
made at a 90-degree angle and the tissue is not bunched. For men
and women who weigh 130-152 lbs (60-70 kg), a 1-inch needle is
sufficient. For women who weigh 152-200 lbs (70-90 kg) and men
who weigh 152-260 lbs (70-118 kg), a 1- to 1.5-inch needle is
recommended. For women who weigh >200 lbs (>90 kg) or men who
weigh >260 lbs (>118 kg), a 1.5-inch needle is recommended (table
6-2) .

• Subcutaneous injections are administered at a 45-degree angle,

usually into the thigh for infants aged <12 months and in the upperouter triceps area of persons aged ≥12 months. Subcutaneous
injections may be administered into the upper-outer triceps area of
an infant if necessary. A ⅝-inch, 23- to 25-gauge needle should be
inserted into the subcutaneous tissue

• If multiple vaccines are administered at a single visit, administer

each preparation at a different anatomic site (28). The location of all
injection sites with the corresponding vaccine injected should be
documented in each patient’s medical record. Health-care practices
should consider using a vaccination site map so that all persons
administering vaccines routinely use a particular anatomic site for
each particular vaccine.

Methods for Alleviating Discomfort and Pain Associated with Vaccination
•
•

Comfort measures, such as distraction, cooling of the injection site(s), topical analgesia,

•

Use of a topical refrigerant spray immediately before vaccination can reduce the short-term pain associated with injections
and can be as effective as lidocaine-prilocaine cream.

•

Evidence does not support use of antipyretics before or at the time of vaccination; however, they can be used for the
treatment of fever and local discomfort that might occur following vaccination.

Pretreatment (30-60 minutes before injection) with a 5% topical lidocaine-prilocaine emulsion might decrease the pain of
vaccination by causing superficial anesthesia . Evidence indicates that this cream does not interfere with the immune
response to MMR . There is no evidence the cream interferes with other vaccines .

https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/administration.html

STEP ONE
ACTIVITY
ASSESS

Using the tool provided perform a self
assessment of your competency for vaccine
administration
https://www.immunize.org/catg.d/p7010.pdf

SKILLS CHECKLIST

Perform
self assessment:
Identify areas
for
Skills enhancement

WHAT ARE THE
AREAS THAT NEED
ENHANCEMENT?
WHERE CAN YOU
FIND THE
EDUCATIONAL AND
TRAINING
RESOURCES?

OBTAIN INFORMED CONSENT
FROM THE ADULT RECEIVING THE
VACCINE
OR THE LEGAL GUARDIAN OF THE
PERSON RECEIVING THE VACCINE

• CDC recommends using ABHR with 6095% alcohol in healthcare settings.

BEFORE YOU
VACCINATE:
GET READY

• Unless hands are visibly soiled, an
alcohol-based hand rub is preferred over
soap and water in most clinical situations
due to evidence of better compliance
compared to soap and water.

GLOVES AND VACCINE ADMINISTRATION
•

Health care personnel should always perform hand hygiene before
administering vaccines by any route. Occupational Safety and Health
Administration (OSHA) regulations typically do not required gloves to be
worn when administering vaccines unless the person administering the
vaccine is likely to come in contact with potentially infectious body fluids
or has open lesions on the hands. During the COVID-19 pandemic,
gloves should be worn when administering intranasal or oral vaccines. If
gloves are worn, they should be changed, and hand hygiene should be
performed between patients.

PREVENT INJURY
• Sharps Disposal Containers are for Needles
and Sharps Only •

• Place only needles and sharps in sharps
disposal containers.

• • Do not put anything in sharps disposal
containers that can be placed in regular
waste containers (such as uncontaminated
trash, gauze, alcohol pads, needle caps, and
gloves).

SAFE USE OF SHARPS

MITIGATE RISK
• Do not remove, recap, break, or bend contaminated needles or separate
contaminated needles from syringes before discarding them into a sharps
disposal container as this increases the risk of a needlestick injury and a
bloodborne pathogen exposure. Best practice is to immediately place the
connected needle and syringe into the sharps disposal container.

DISPOSAL OF SHARPS
• If you experience a needlestick from a used or contaminated needle, seek
immediate evaluation and treatment. Call the PEP (post-exposure prophylaxis)
hotline at 1–888–448–4911 immediately for guidance on treating exposures.

Safe Sharps Disposal
• SafeNeedleDisposal.org https://safeneedledisposal.org Food and Drug Administration (FDA):
•

How to get rid of a sharps container

https://www.fda.gov/files/medical%20devices/ published/How-to-Get-Rid-of-a-SharpsContainer--Printable-Version.pdf

NEED A
TRAINING
CERTIFICATE?

https://tceols.cdc.gov/

3: TRAINING AND CERTIFICATION

Complete the
https://www.cdc.gov/vaccines/ed/youcalltheshots.html
Upload the certificate

MODULE 6: APPLICATION
In this module the learner will use the knowledge and skills attained in this
course to access the appropriate resources to make clinical decisions using the
most current and up to date resources

CASE STUDY 1
Mary is a 65 year old woman with Hypertension and psoriasis . She is treated
with metoprolol 25 mg po qd and methotrexate 30 mg po once weekly. Her
Vital signs are T 100.1 , BP 138/90 HR 68 and Pulse oximetry 98%
She comes to the vaccination clinic today asking for the “Shingles vaccine”
and a “Whooping Cough vaccine” because she has a new grandchild. She
states, “ My son will not let me see the baby until I have all my shots”.

➢ What education will the healthcare provider present?
➢ What requested vaccines will Mary safely receive today?

CASE STUDY 2
Jennifer is a 35 year old RN who presents to the employee health clinic for an annual
influenza vaccine and evaluation. She works in the Labor and Delivery area. She
received a Td vaccine 8 years ago. Her Measles titer reflects she is not immune; she
expresses concern regarding this and states “I have been trying to get pregnant,
please give me the MMR today, I am going for an invitro next month.”

➢What education will the healthcare provider present?

➢ What requested vaccines will Jennifer

safely receive today?

CASE STUDY 3
Robert is a 68 year old bus driver who visits the clinic today requesting his annual
influenza vaccine. He states,” I came here today because I don’t want to get the flu;
last year was a bad year, I had the flu, my wife had Covid and I had shingles.”
After collecting a history, you learn that Robert reports: “My grandson is 3 months old;
he lives with us.”
Robert’s last immunization was 5 years ago for a Td following a laceration to his foot
while doing home improvements. He has never received a MMR or Varicella vaccine.

➢What additional vaccines will be required and why?
➢ What requested vaccines will Robert safely receive today?

CASE STUDY 4
Joseph is a 24 year old hospital worker who comes to the vaccination clinic today
requesting a Covid vaccine. He has recently immigrated to the United States and does
not have any record of his vaccinations given in childhood. He reports that he is
sexually active and is bisexual. He comes to the clinic today requesting a COVID
vaccine stating “ If I don’t get the vaccine today, I will lose my job”. His vitals signs
are 101.7, he has a cough. His BP is 150/90, Pulse ox 94%

➢What requested vaccines will he safely receive today?
➢What CDC recommended vaccines should Joseph be scheduled to receive?
➢ After reviewing the adult immunization catch up schedule, the provider
determines that Joseph is eligible for which vaccines?

CASE STUDY 5
Jane (she) is a 45-year-old transgender female who comes to the vaccine clinic
requested the shingles vaccine. She reports that she had a Moderna Covid vaccine 12
months ago but did not return for the second dose. She asks is she needs to start
over. What requested vaccines will Robert safely receive today?

➢What CDC recommended vaccines should Jane be scheduled to receive?
➢ What actin will the provider take to address the question about Covid vaccination?
➢After reviewing the adult immunization schedule, the provider determines that
Jane is potentially eligible for which vaccines?

CASE STUDY 6
Yvonne is a 65-year-old female who comes to the vaccine clinic requesting
the Influenza vaccine and Moderna Covid vaccine. She reports that she had a
Johnson and Johnson Covid vaccine 6 months ago. She received Shingrix at
age 60 and received Tdap 8 years ago.

➢What CDC recommended vaccines should Yvonne be scheduled to receive?
➢ What action will the provider take to address the question about Covid
vaccination?

➢After reviewing the adult immunization

schedule, the provider determines
that Yvonne is potentially eligible for which vaccines?

